Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer | Zendy

Emel Canbay | Zendy; Bahar Canbay Torun | Zendy; K Cosarcan | Zendy; Cetin Altunal | Zendy; Bülent Gürbüz | Zendy; Çağrı Bilgiç | Zendy; Canfeza Sezgin | Zendy; Kerim Kaban | Zendy; Serpil Yılmaz | Zendy; Zeliha Yazıcı | Zendy

Open Access

Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer

Author(s) -

Emel Canbay,

Bahar Canbay Torun,

K Cosarcan,

Cetin Altunal,

Bülent Gürbüz,

Çağrı Bilgiç,

Canfeza Sezgin,

Kerim Kaban,

Serpil Yılmaz,

Zeliha Yazıcı

Publication year - 2021

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo-20-121

Subject(s) - medicine , docetaxel , hyperthermic intraperitoneal chemotherapy , ascites , gastrectomy , cisplatin , chemotherapy , surgery , induction chemotherapy , cancer , conventional pci , gastroenterology , ovarian cancer , cytoreductive surgery , myocardial infarction

Gastric cancer (GC) with peritoneal metastases (PM) has a dismal prognosis and to date only a few management options have been reported. Of those, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after induction bidirectional intraperitoneal and systemic chemotherapy (BIPSC) appear as a promising treatment option for these patients. Outcome data including safety and efficacy of CRS with radical Gastrectomy and HIPEC after response to combination of laparoscopic HIPEC (LHIPEC) with BIPSC as an induction therapy in patients with PM of GC was evaluated in this retrospective observational study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research